We are live on
!
Find out more
ACM
Atika Capital Management Portfolio holdings
AUM
$796M
1-Year Est. Return
167.57%
This Fund
S&P 500
This Quarter
Est. Return
+23.34%
1 Year Est. Return
+167.57%
3 Year Est. Return
+553.47%
5 Year Est. Return
+1,283.26%
10 Year Est. Return
+44,203.78%
AUM
$509M
AUM Growth
+$16.9M
(+3.4%)
Cap. Flow
-$34.9M
Cap. Flow
% of AUM
-6.86%
Top 10 Holdings %
Top 10 Hldgs %
30.28%
Holding
101
New
29
Increased
19
Reduced
23
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CarMax
KMX
|
+$11.7M |
| 2 |
Walt Disney
DIS
|
+$8.09M |
| 3 |
Beyond Meat
BYND
|
+$7.92M |
| 4 |
HEICO Corp Class A
HEI.A
|
+$7.1M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
+$6.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madison Square Garden
MSGS
|
+$6.89M |
| 2 |
ZEN
ZENDESK INC
ZEN
|
+$6.12M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$4.78M |
| 4 |
Boeing
BA
|
+$4.58M |
| 5 |
Ashland
ASH
|
+$4.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.67% |
| 2 | Technology | 20.5% |
| 3 | Communication Services | 11.6% |
| 4 | Consumer Discretionary | 11.08% |
| 5 | Materials | 3.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADVM
51
DELISTED
Adverum Biotechnologies
ADVM
| $4.39M | 0.86% |
+36,900
| New | +$3.05M |
|
52
Twilio
TWLO
$30.3B
| $4.36M | 0.86% |
+32,000
| New | +$4.26M |
|
|
GWPH
53
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $4.31M | 0.85% |
25,000
| – | – |
|
|
XYZ
54
Block Inc
XYZ
$48.7B
| $4.13M | 0.81% |
57,000
-31,000
| -35% | -$2.17M |
|
55
Guardant Health
GH
$21.6B
| $4.06M | 0.8% |
47,000
-10,000
| -18% | -$764K |
|
56
Veracyte
VCYT
$3.61B
| $3.9M | 0.77% |
+137,000
| New | +$3.42M |
|
|
GOOS
57
Canada Goose Holdings
GOOS
$866M
| $3.87M | 0.76% |
100,000
-25,000
| -20% | -$1.13M |
|
58
Brink's
BCO
$4.78B
| $3.82M | 0.75% |
+47,000
| New | +$3.74M |
|
|
TWTR
59
DELISTED
Twitter, Inc.
TWTR
| $3.49M | 0.69% |
+100,000
| New | +$3.67M |
|
|
ARQL
60
DELISTED
Arqule Inc
ARQL
| $3.49M | 0.69% |
+317,000
| New | +$2.21M |
|
61
PTC Therapeutics
PTCT
$5.68B
| $3.38M | 0.66% |
+75,000
| New | +$2.96M |
|
62
Zoom
ZM
$28.8B
| $3.29M | 0.65% |
+37,000
| New | +$3.04M |
|
|
63
Ashland
ASH
$3.27B
| $3.04M | 0.6% |
38,000
-59,000
| -61% | -$4.56M |
|
|
PTLA
64
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $2.71M | 0.53% |
100,000
| – | – |
|
|
CTLT
65
CALL
DELISTED
CATALENT, INC.
CTLT
| $2.71M | 0.53% |
+50,000
| New | +$2.29M |
|
|
MDCO
66
DELISTED
Medicines Co
MDCO
| $2.59M | 0.51% |
+71,000
| New | +$2.32M |
|
|
VAR
67
DELISTED
Varian Medical Systems, Inc.
VAR
| $2.59M | 0.51% |
19,000
-30,000
| -61% | -$4.01M |
|
|
LKFT
68
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.75B
| $2.45M | 0.48% |
19,000
| – | – |
|
69
NovoCure
NVCR
$1.77B
| $2.09M | 0.41% |
32,990
-25,010
| -43% | -$1.27M |
|
|
ZGNX
70
DELISTED
Zogenix, Inc.
ZGNX
| $1.91M | 0.38% |
40,000
-36,000
| -47% | -$1.45M |
|
71
Anterix
ATEX
$1.83B
| $1.79M | 0.35% |
38,000
| – | – |
|
72
CALL
Madrigal Pharmaceuticals
MDGL
$10.9B
| $1.78M | 0.35% |
17,000
-10,000
| -37% | -$1.07M |
|
73
Ultragenyx Pharmaceutical
RARE
$2.46B
| $1.78M | 0.35% |
+28,000
| New | +$1.78M |
|
74
Molina Healthcare
MOH
$10.2B
| $1.72M | 0.34% |
12,000
-9,000
| -43% | -$1.23M |
|
75
Rocket Pharmaceuticals
RCKT
$366M
| $1.54M | 0.3% |
+102,600
| New | +$1.79M |
|
Similar funds
AGA
RIM
ACM
CAM
LSA
GWA
HP
Atika Capital Management's Q2 2019 Portfolio in Review
As of Q2 2019, Atika Capital Management held 101 positions worth $509M, up 3.4% from $492M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Atika Capital Management withdrew a net $34.9M in Q2 2019, closing 24 positions and reducing 23 holdings. Its most notable exit was Madison Square Garden, an estimated $6.89M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 29% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Atika Capital Management opened a new position in CarMax worth $13M.
- Atika Capital Management's largest Q2 2019 buy was CarMax: 150,000 shares worth $13M.
- Atika Capital Management added most to Martin Marietta Materials in Q2 2019, an estimated $3.03M increase.
- Atika Capital Management's biggest Q2 2019 reduction was Ashland, cutting an estimated $4.56M.
- Atika Capital Management fully exited Madison Square Garden in Q2 2019, selling an estimated $6.89M.
- Atika Capital Management's ten largest holdings make up 30% of its $509M portfolio in Q2 2019.
- Atika Capital Management opened 29 new positions and closed 24 in Q2 2019.
- Atika Capital Management's portfolio value rose 3.4% quarter-over-quarter to $509M.
Based on Atika Capital Management's 13F filing for Q2 2019, filed 12 Aug 2019.